These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2855291)

  • 21. An active fraction of unfractionated heparin from a natural source is recognized by the first component of the complement system.
    Calabrese GC; Leocatanieto F; Recondo EF; Fernandez de Recondo ME
    Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL119-23. PubMed ID: 11936856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Autoantibodies to heparin polysaccharides bind to vascular endothelial cells].
    Shibata S
    Rinsho Byori; 1998 Dec; 46(12):1205-9. PubMed ID: 9916505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
    Turk B; Brieditis I; Bock SC; Olson ST; Björk I
    Biochemistry; 1997 Jun; 36(22):6682-91. PubMed ID: 9184148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin.
    Brieger D; Dawes J
    Thromb Haemost; 1996 May; 75(5):740-6. PubMed ID: 8725716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycosaminoglycans as naturally occurring combinatorial libraries: developing a mass spectrometry-based strategy for characterization of anti-thrombin interaction with low molecular weight heparin and heparin oligomers.
    Abzalimov RR; Dubin PL; Kaltashov IA
    Anal Chem; 2007 Aug; 79(16):6055-63. PubMed ID: 17658885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sera, basic fibroblast growth factor, heparin and cyclic AMP-stimulation on proliferation of human vascular endothelial cells.
    Gillis C; Jonzon B; Haegerstrand A
    Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1131-8. PubMed ID: 8747094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anticoagulating activity and lytic action of the heparin-antithrombin III and antithrombin III-heparin-thrombin complexes on non-stabilized fibrin].
    Kudriashov BA; Pastorova VE; Liapina LA
    Biokhimiia; 1981 Nov; 46(11):2024-9. PubMed ID: 7317530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of haemostasis in an in vitro model of the pig-to-human xenograft reaction.
    Jurd KM; Cairns T; Hunt BJ
    Transplant Proc; 1994 Jun; 26(3):1159-60. PubMed ID: 8029868
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro.
    Larnkjaer A; Ostergaard PB; Flodgaard HJ
    Thromb Res; 1994 Jul; 75(2):185-94. PubMed ID: 7974392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uptake and inactivation of thrombin by the fresh, glutardialdehyde or heparin treated human umbilical cord vein endothelium.
    Björck C; Larsson R; Olsson P; Rothman U
    Thromb Res; 1981 Mar; 21(6):603-9. PubMed ID: 6791299
    [No Abstract]   [Full Text] [Related]  

  • 33. Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells.
    Vannucchi S; Pasquali F; Porciatti F; Chiarugi V; Magnelli L; Bianchini P
    Thromb Res; 1988 Feb; 49(4):373-83. PubMed ID: 2837834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic levels of nitroglycerin do not affect the uptake and release of heparin by endothelial cells in vitro.
    Brack MJ; More RS; Spring E; Gershlick AH
    Thromb Res; 1993 May; 70(4):329-35. PubMed ID: 8332962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin stimulates the release of glycosaminoglycans from cultured human endothelial cells.
    Kaji T; Sakuragawa N
    Thromb Res; 1990 Jan; 57(1):163-8. PubMed ID: 2300921
    [No Abstract]   [Full Text] [Related]  

  • 36. Only excessive III concentrations release prostacyclin in human dermal microvascular cells.
    Mittermayr M; Lercher A; Kountchev A; Schobersberger W; Sepp N
    J Thromb Haemost; 2003 Jan; 1(1):197-9. PubMed ID: 12871564
    [No Abstract]   [Full Text] [Related]  

  • 37. Binding of low-molecular-weight heparin to aortic endothelium in rabbits.
    Gensini GF; Fortini A; Lombardi A; Pesciullesi E; Pieroni C; Neri Serneri GG
    Haemostasis; 1984; 14(6):466-72. PubMed ID: 6534819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding of heparin to antithrombin III: The use of dansyl and rhodamine labels.
    Piepkorn MW; Lagunoff D; Schmer G
    Arch Biochem Biophys; 1980 Dec; 205(2):315-22. PubMed ID: 7469415
    [No Abstract]   [Full Text] [Related]  

  • 39. An unknown FVIII-inactivating substance derived from endothelial cells inhibits the intrinsic tenase complex.
    Bombeli T; Woodtli K; Haeberli A
    Thromb Res; 2001 Jan; 101(2):83-9. PubMed ID: 11342209
    [No Abstract]   [Full Text] [Related]  

  • 40. Tissue average binding and equilibrium distribution: an example with heparin in arterial tissues.
    Lovich MA; Edelman ER
    Biophys J; 1996 Mar; 70(3):1553-9. PubMed ID: 8785313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.